跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

B6769

Sigma-Aldrich

des-Arg9-[Leu8]-缓激肽 乙酸盐

≥97% (HPLC)

别名:

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C41H63N11O10
CAS号:
115035-45-5
分子量:
870.01
MDL號碼:
MFCD00133250
分類程式碼代碼:
12352209
PubChem物質ID:
329773283
NACRES:
NA.26

product name

des-Arg9-[Leu8]-缓激肽 乙酸盐, ≥97% (HPLC)

品質等級

200

化驗

≥97% (HPLC)

形狀

powder

顏色

white

儲存溫度

−20°C

SMILES 字串

CC(O)=O.CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@@H](N)CCCNC(N)=N)C(O)=O

InChI

1S/C41H63N11O10.C2H4O2/c1-24(2)20-28(40(61)62)48-36(57)31-14-8-17-50(31)38(59)29(23-53)49-34(55)27(21-25-10-4-3-5-11-25)47-33(54)22-46-35(56)30-13-7-18-51(30)39(60)32-15-9-19-52(32)37(58)26(42)12-6-16-45-41(43)44;1-2(3)4/h3-5,10-11,24,26-32,53H,6-9,12-23,42H2,1-2H3,(H,46,56)(H,47,54)(H,48,57)(H,49,55)(H,61,62)(H4,43,44,45);1H3,(H,3,4)/t26-,27-,28-,29-,30-,31-,32-;/m0./s1

InChI 密鑰

XBFMNOKHQZCARQ-XXZMQFNDSA-N

相关类别

Amino Acid Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu

應用

The Bradkykinin amid peptide des-Arg9-[Leu8]-Bradykinin is used as a bradykinin-1 receptor (B1R) antagonist frequently in comparison with the B1 receptor agonist des-Arg9-bradykinin.

生化／生理作用

缓激肽受体拮抗剂。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M M Campos et al.
British journal of pharmacology, 117(5), 793-798 (1996-03-01)
1. The effect of pretreatment with bacterial endotoxin (LPS, 10 micrograms, i.v., 24 h) on the bradykinin B1 and B2 receptor-induced oedema in the rat paw, and the interaction of B1-mediated responses with other inflammatory mediators, was investigated. 2. Intraplantar
Juliano Ferreira et al.
Neuropharmacology, 54(3), 597-604 (2008-01-01)
The peripheral injection of phorbol myristate acetate (PMA) into the mouse paw induces nociception mediated through activation of protein kinase C (PKC). In the present study, we examine the contribution of kinin B1 receptor to PMA-induced nociception. Nociception was assessed
Thomas A Barker et al.
Hypertension (Dallas, Tex. : 1979), 48(5), 942-949 (2006-09-20)
It has been suggested that the effects of angiotensin II type 1 receptor (AT1R) blockers are in part because of angiotensin II type 2 receptor (AT2R) signaling. Interactions between the AT2R and kinins modulate cardiovascular function. Because AT2R expression increases

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门